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The incidence of airflow obstruction in bronchial 
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*National Heart and Lung Institute, London, and TRegional Cardiothoracic Unit, Killingbeck Hospital, 
Leeds. U.K. 
Breathlessness is a common symptom in patients with primary bronchial carcinoma and is often not 
well-controlled. Most patients are ex- or current smokers, and therefore are at high risk for co-existing chronic 
obstructive pulmonary disease (COPD). The incidence of airflow obstruction in patients with bronchial 
carcinoma, its relation to breathlessness, and response to bronchodilator therapy was examined prospectively. 
Fifty-seven consecutive patients attending our outpatient clinic with bronchial carcinoma diagnosed in the 
preceding 12 months were studied (22 female, 35 male, mean age 68.4 years). Spirometry was performed and 
breathlessness rated. Those with airflow obstruction (FEV,:FVC<65% and FEV,c70% predicted) and who 
judged themselves to have moderate or severe breathlessness, were offered a trial of bronchodilator therapy. 
The response to regular inhaled fenoterol and ipratropium bromide by metered dose inhaler (MDI) and large 
volume spacer, and to regular nebulized salbutamol and ipratropium bromide was assessed by home peak flow 
recordings, spirometry and two subjective scores: (a) rating of breathlessness on a simple four-point scale, and 
(b) activity score of the St George’s Respiratory Questionnaire. There was very strong association between 
airflow obstruction and breathlessness. Twenty-eight patients (49%) had airflow obstruction, and we had 
breathlessness ratings on 26 of these patients of whom 18 (69%) had rated it as moderate or severe. Only four 
of the patients with airflow obstruction and breathlessness were using bronchodilator therapy. There was no 
significant difference in the mean age, time from diagnosis, tumour site, or smoking history between the 
groups with, and without, airflow obstruction. There was no association between cell type and the presence of 
airflow obstruction. 
Seventeen patients accepted the offer of a trial of bronchodilator therapy, of whom 15 patients remained 
well enough to complete it. Home peak expiratory flow rate (PEFR), rose from 233 1 min- ’ to 247 1 min - ’ 
with MD1 bronchodilators, and to 256 1 min - I with nebulized bronchodilators. Mean FEVi rose from 1.18 1 
to 1.31 1 following 2 weeks of MD1 bronchodilators, and to 1.35 1 with nebulized drugs. For the group, there 
was no additional benefit from nebuliied drugs over the MDI. Eight patients showed objective improvement - 
PEFR and/or FEV, increasing by r 15% of baseline. Nine patients felt that their breathing had been helped 
‘quite a lot’ or ‘a great deal’, but four patients had not experienced objective benefit. Breathlessness rating 
improved significantly following bronchodilators, falling from 2.53 pre-treatment to 1.87 following MD1 use, 
and to 1.79 with nebulized drugs. There was no significant improvement in mean activity scores. We conclude 
that untreated airflow obstruction is commonly present in patients with bronchial carcinoma, is strongly 
associated with breathlessness, and that these patients may benefit from simple bronchodilator treatment. 
Introduction 
Breathlessness is a common symptom in bronchial 
carcinoma and is generally not well controlled (1,2). 
The majority of patients have a smoking history and 
are therefore at risk of co-existing, cigarette-related 
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COPD. The aim of this prospective study was to 
examine the incidence of airflow obstruction in 
patients with bronchial carcinoma, its relation to 
breathlessness and to assess response to bronchodi- 
lator treatment. 
Patients and Methods 
Fifty-seven consecutive patients with a diagnosis 
of bronchial carcinoma made in the preceding 
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12 months attending our outpatient respiratory clinic 
were assessed. The diagnosis of bronchial carcinoma 
was made on the basis of typical bronchoscopic 
appearance and usually confirmatory histology, or 
cytological confirmation of a chest X-ray lesion. Our 
intention was to assess people in a stable condition, 
and those who were receiving anti-cancer treatment 
were studied more than 3 weeks after completion of 
their treatment course. Details of cell type, site of 
tumour and past cigarette consumption were 
recorded. Site of tumour was recorded as ‘large 
airway’ if viewed in, or more proximal to, a lobar 
bronchus at bronchoscopy, and ‘peripheral’ if posi- 
tioned in a segmental bronchus or beyond, or not 
seen at bronchoscopy. All patients were screened 
with a simple breathlessness questionnaire (see 
appendix), and considered to have troublesome 
breathlessness if they were rated at two or more, i.e. 
judged their breathlessness to be moderate or severe. 
Spirometry was measured in all patients by an experi- 
enced operator, and recorded as the best of three 
blows taken >4 h after any bronchodilator therapy 
(Vitalograph dry wedge spirometer). We defined air- 
flow obstruction to be present if the FEV,:FVC ratio 
was ~65% and FEV, was ~70% predicted. If both a 
breathlessness rating of 22 and airflow obstruction 
were present, the patient was offered a trial of 
bronchodilator treatment. 
TRIAL OF BRONCHODILATOR TREATMENT 
The patients recorded 1 week’s baseline home peak 
expiratory flow rate (PEFR) after laboratory instruc- 
tion, using a mini Wright PEF meter (Clement 
Clarke International) twice daily on waking and at 
bedtime, always before any bronchodilator medica- 
tion (best of three blows). PEFR was analysed by 
taking the mean of the preceding week’s readings. 
Baseline spirometry and reversibility to nebulized 
salbutamol [5 mg (5 min)] and ipratropium bromide 
[500 ,ug (40 min)], were recorded prior to entering the 
bronchodilator trial. The activity component of the 
St George’s Respiratory Questionnaire (SGRQ) (3) 
was administered to the patient by a technician. This 
is a standardized and validated quality-of-life assess- 
ment for airways disease. The activity component 
consists of questions relating to activities of daily 
living that cause or are impaired by breathlessness. 
The responses are weighted and the final score lies 
between O-100, a higher score indicating more severe 
impairment. A randomized, open-crossover study of 
two treatment regimens was then commenced. Regi- 
men A: fenoterol (180 pg) + ipratropium bromide 
(8Opg) four times daily via a MD1 in a large 
volume spacer (Volumatic Allen & Hamburys), and 
B: salbutamol (5 mg) and ipratropium bromide 
(5OOpg) via a nebulizer (Medix x 2000 compressor 
with a Unimed Inspiron nebulizer) four times daily. 
The patients were instructed how to use these devices 
and continued to record their PEFR on waking and 
at bedtime. Each treatment was carried out for a 
2-week period at the end of which spirometry, 
breathlessness rating and the SGRQ activity score 
were repeated. The patients were also asked how 
much they felt that the treatment had helped them 
(see Appendix). No additional medication that may 
have affected breathlessness (particularly corticoster- 
oids or opiates) were prescribed for the trial period. 
At the end of the trial the patients were asked which 
treatment, if any, they preferred and the most appro- 
priate for each patient was continued. The study 
was approved by our local clinical research ethics 
committee. 
Statistical analysis was carried out using paired 
and unpaired t-tests, Mann-Whitney U-test and 
Wilcoxon-signed rank test for non-parametric data, 
and Chi-squared or Fisher’s exact test for contin- 
gency tables. Significance was taken at the 0.05 
level. Results are expressed as mean (SD) and 95% 
confidence intervals (CI). 
Results 
INITIAL SURVEY 
Of the 57 patients surveyed, data was incomplete in 
three patients due to loss of the separate sheet used to 
assess breathlessness. All 57 patients were included in 
the analysis, except for results relating to breathless- 
ness where the 54 patients with complete data were 
analysed. Mean age was 68.4 years (range 43-81), 22 
of the patients were women. Mean spirometric values 
were: FEV, 1.55 (0.58) 1, (66.4% of predicted), FVC 
2.49 (0.80) 1, FEV,/FVC 62.5 (13.3%). Mean time 
from initial diagnosis was 4.4 (3.36) months. Cell 
type was as follows; 21 squamous cell, 11 small cell, 
10 large cell, nine adenocarcinoma; the remaining six 
were undifferentiated (1) and not established (5). The 
five patients with no histological proof, had typical 
clinical and radiographic features of primary bron- 
chial carcinoma. They had progressive abnormalities 
on their radiographs and their clinical course was 
entirely consistent with carcinoma. Treatment 
received (relating to carcinoma) is detailed in Table 1. 
Twenty-eight patients (49%) had airflow obstruc- 
tion. Of those in whom we had complete data (26 
patients), 18 (69%) had troublesome breathlessness. 
Only three of 28 patients (11%) with no airflow 
obstruction had troublesome breathlessness 
(P=O.O003) for the association of breathlessness and 
Airflow obstruction in bronchial carcinoma 293 
Table I Anti-cancer treatment received 
Cell type Palliative DXT Radical DXT Chemotherapy Surgery Nil 
Squamous n=21 10 (48%)* 2 (9.5%) 3 (14%)? 6 (28.5%) 
Small cell n = 11 11 (lOO%)f 
Large cell n = 10 5 (50%) 1 (10%) 1 (10%) 3 (30%) 
Adenocarcinoma n=9 3 (33%) 6 (67%) 
Other n=6 1 (17%) - 5 (83%) 
*Includes three patients who received palliative endobronchial radiotherapy, tthree patients received post-operative 
radiotherapy, $EIMV, three patients received radiotherapy post-chemotherapy. 
Table 2 Comparison of groups 
Age Cell type 
Mean (SD) (years) (sq,sc,lc,a) 
Tumour site 
(la,p) 
Time from 
diagnosis Cigarettes 
months (pa&yrs) 
SOB 
rating 
(n=54) 
FEVJFVC 
WJO) 
Airflow obstruction 
n=28 n=26 
F:M=9/19 70.3 (8.6) 6,5,6,7 12,14 3.86 (3.7) 48.6 (32) 1.96 (0.92) 50.9 (8.3) 
No airflow obstruction 
n=29 n=28 
F:M=13/16 66.5 (8.3) 15,6,4,2 19,lO 4.93 (3.0) 43.9 (25) 0.68 (0.86) 73.2 (6.7) 
Sex ratio n.s. n.s. tl.S. ns. KS. n.s. P<0~0001 P<0~0001 
Chi-squared Fisher’s exact test Mann-Whitney U t-test 
sq, squamous cell; SC, small cell; lc, large cell; a, adenocarcinoma; la, large airway; p. peripheral; F, female; M, male. 
airflow obstruction (Fisher’s exact test). There was 
no difference in age, time from diagnosis or quantity 
of cigarettes smoked between the groups with, and 
without, airflow obstruction (Table 2). There was a 
highly-significant difference in breathlessness rating 
between the groups with, and without, airflow 
obstruction [ 1.96 (O-92) vs. 0.68 (0.86), (CI 0.81-l .81, 
PcO.0001 Mann-Whitney U-test)]. There was no 
difference in tumour site between the groups and no 
significant differences between cell type. 
TRIAL OF BRONCHODILATOR THERAPY 
The 18 patients with both breathlessness and air- 
flow obstruction were offered a trial of bronchodila- 
tor treatment. One patient declined. Two patients 
were withdrawn before completion; one patient 
developed a large pleural effusion, requiring chest 
drainage, and the other patient developed symptom- 
atic hypercalcaemia. Results from the remaining 15 
patients were analysed, one of whom completed only 
one treatment arm (see below). One patient did not 
record home PEFR. Four patients had received 
radiotherapy, the course having been completed at 
4, 11, 13 and 18 weeks respectively, prior to the 
nebulizer trial commencing. None of the patients had 
been recently treated with chemotherapy or surgery. 
Mean baseline FEV,:FVC ratio for the group was 
54.7 (9.6)%. Home PEFR at baseline was 233 
(68)lmiK’, and improved to 247 (66) 1 min- 1 with 
the MD1 (P=O.Ol paired t-test, CI 3.8-23.3), and 256 
(56) 1 min ~ ’ with nebulized drugs (P=O.Ol, CI 4.1- 
28.2). Mean FEV, increased from 1.18 (0.38) 1 to 1.31 
(0.45) 1 following 2 weeks of bronchodilators via the 
MDI, (P=O.Ol, CI 0.04-0.22). There was no further 
increase with nebulized bronchodilators. Mean FVC 
increased from 2.2 (0.77) 1 to 2.43 (0.88) 1 following 
bronchodilators via the MDI, (P=O.O3, CI 0.09- 
0.36). Again for the group, there was no further 
increase following nebulized bronchodilators (Table 
3). Breathlessness ratings improved significantly; 
mean rating 2.53 (0.52) prior to treatment, 1.87 (0.92) 
with MD1 (P=O.OOS Wilcoxon-signed rank test) and 
1.79 (0.7) with nebulized drugs (P=O.O02). Eight 
patients moved to a lower rating on the MD1 and 10 
patients moved to a lower rating on the nebulizer 
(Table 4). The SGRQ activity score improved by 
more than 10 points in seven patients, but there was 
no change in mean score. The extent to which the 
patients felt treatment had helped are shown in Fig. 
1. Eight patients had a rise in either, or both, FEV, 
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Table 3 Response to bronchodilator therapy 
Baseline After 2 weeks MD1 After 2 weeks nebulizer 
FEV, 1.18 (0.38) 1.31 (0.45) 1.35 (0.53) 
P=O.Ol P=O.O3 
FVC 2.20 (0.77) 2.43 (0.88) 2.49 (0.82) 
P=O-003 P=O.O08 
PEFR 233.2 (67.6) 246.8 (65.5) 255.8 (55.8) 
P=O.OOl P=O.Ol 
SGRQ 59 (19.4)0? 55 (24,0)% 57 (23)‘Xo 
n.s. n.s. 
Breathlessness 
rating mean 2.53 (1.52) 1.87 (0.92) 1.79 (0.7) 
P=O.O08 P=O.O02 Wilcoxon-signed rank 
P values are for differences from baseline; difference between MD1 and nebulizer not significant in all cases; PEFR, peak 
expiratory flow rate; SGRQ, St George’s Respiratory Questionnaire. 
Table 4 Breathlessness ratings 
Patient no. Pre-treatment MD1 Nebulizer 
1 2 
2 2 
3 2 
4 3 
5 2 
6 3 
7 2 
8 3 
9 3 
10 3 
11 3 
12 3 
13 2 
14 2 
15 3 
mean 2.53 
2 
2 
2 
3 
0 
2 
2 
2 
2 
2 
3 
2 
0 
3 
1.87 
2 
2 
3 
2 
2 
3 
2 
2 
2 
1 
1.79 
MDI, metered dose inhaler. 
and PEFR of >lS% (three patients FEV, only, two 
patients PEFR only, three patients both). Five of 
these patients felt their breathing had been helped 
‘quite a lot’ or ‘a great deal’ although three patients 
felt that they had only been helped ‘a little’. Con- 
versely, there were four patients who felt that their 
breathing had been helped ‘quite a lot’ or ‘a great 
deal’, who did not show objective benefit as judged 
by a rise in FEV, or PEFR by > 15%. Two patients 
were unable to tolerate the nebulizer and one patient 
found the MD1 with spacer so beneficial that she did 
not want to try the nebulizer. Of the 14 patients that 
did try both treatments, seven patients preferred 
the MD1 with spacer, four patients preferred the 
nebulizer and patients who had not felt subjective 
improvement, had no preference. There was no 
additional improvement in FEV, or PEFR from the 
nebulizer over the MD1 in 12 patients. Laboratory 
reversibility testing predicted objective response cor- 
rectly in 10 patients, but reliance on this would have 
excluded two patients who gained both objective and 
good subjective benefit. Correlation between labora- 
tory reversibility and both change in FEV, and 
PEFR was poor (r=0.47 for FEV,, rz0.38 for 
PEFR, Pearson’s correlation coefficient). There was 
no difference in FEV,: FVC ratio, FEV,, PEFR or 
age between the groups that did, and did not, gain 
objective benefit. 
Discussion 
Breathlessness is a common symptom in all types 
of cancer, but is more common in bronchial carci- 
noma (4). Attempted palliation may be specific, e.g. 
drainage of a pleural effusion, treatment of large 
airway obstruction by stents or radiotherapy, or 
non-specific, e.g. using opiates or oxygen. As 
expected, overall our patients had a high incidence of 
breathlessness (39%). These patients were under 
active follow-up and attending a chest clinic, and 
may have been at an earlier stage of their disease than 
in other studies carried out in a palliative care setting 
(1,4). Despite this, we found a comparable incidence 
of breathlessness. In the study by Higginson and 
McCarthy (l), breathlessness was the main symptom 
in 30% of patients with bronchial carcinoma at the 
time of referral to a district terminal care support 
team. Breathlessness appeared to worsen with time 
whereas pain, which was the main symptom in an 
equal number initially, became less of a problem. The 
Yorkshire Thoracic Group study (2) of patients 
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IC 111, 
not at all a little quite a lot a great deal 
Response 
Fig. I Response to the question ‘has the treatment helped your 
breathing .’ 0, metered dose inhaler; n , nebulizer. 
with non-small cell lung cancer referred to chest 
physicians or radiotherapists, found an incidence of 
moderate or severe breathlessness of 41% at presen- 
tation; 65% of patients were breathless 12 months 
before death and this rose to 80% within 2 months of 
death. Palliation is an extremely important aim of 
therapy in bronchial carcinoma, as few patients will 
be cured. In this group, only seven patients (12%) had 
a potentially curative treatment. 
A simple, initial screening, assessment of breath- 
lessness was used in this study as it was felt that an 
activity score may be inaccurate due to the underly- 
ing cancer. However, an activity score was included 
in the bronchodilator trial part of the study. The 
study design needed to take account of the underly- 
ing disease and short prognosis, and we were anxious 
to attain maximum possible benefit with the mini- 
mum disturbance to our patients. Therefore, the trial 
of treatment was only offered to patients with airflow 
obstruction who were symptomatic, and not to 
patients with airflow obstruction who were asymp- 
tomatic (eight patients) or symptomatic patients 
without airilow obstruction (three patients). 
Although we accept that the latter group may have 
been a potentially suitable control set, the number 
of patients would have been far too small to have 
given useful information. The short run in period of 
baseline PEFR monitoring was commenced at the 
patients’ outpatient visit. We did not feel that a 
placebo arm was ethically justified but did randomize 
the order of the treatments. Although fenoterol is not 
usually recommended for asthmatics, on the basis of 
a possible increase in severe attacks, there is no 
evidence of a similar effect in COPD. The combi- 
nation MD1 used has the advantage of convenience 
for the patient. It was interesting to note that the 
majority of patients found the MD1 more beneficial, 
and that two patients were unable to tolerate the 
nebulizer. 
The most striking finding was the very strong 
association between airflow obstruction and breath- 
lessness. Airflow obstruction was unrelated to age, 
total past cigarette consumption or site of tumour. It 
seems likely that the main cause of breathlessness 
in this group of patients was underlying COPD 
rather than bronchial carcinoma. Previous studies 
have suggested that the development of emphysema 
(5), and of airflow obstruction (6,7) in cigarette 
smokers are both independent markers for subse- 
quent development of bronchial carcinoma. An early 
case control study found an increased incidence of 
chronic bronchitis in patients with bronchial carci- 
noma compared to surgical controls (8). In this 
study, the incidence of airflow obstruction was higher 
than that expected for the population of cigarette 
smokers, overall 49% VS. x 15% (9). The fact that 
only four out of 18 patients with breathlessness and 
airflow obstruction were on any type of broncho- 
dilator treatment implies that COPD, as a cause of 
their breathlessness, had been overlooked even in a 
respiratory clinic. Mean FEV, and home PEFR both 
improved significantly with bronchodilator treat- 
ment. There was an increase in one or both of these 
measures >15% in eight of 15 patients, five of whom 
felt that their breathing had been helped ‘quite a lot’ 
or ‘a great deal’. If we use only the criteria of a rise in 
PEFR by 15% as has been suggested (lo), then five of 
15 patients had objective benefit of whom four 
patients felt that they had been helped. However, as 
in other studies (10,l l), there were more patients with 
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subjective improvement than objective improvement 
as judged by PEFR or FEV,. There was a highly- 
significant improvement in the rating of breathless- 
ness following treatment with bronchodilators. Mean 
activity scores did not improve significantly, but did 
not deteriorate either. We considered whether previ- 
ous radiotherapy may have influenced our measure- 
ments but do not think this was the case, because of 
the minimum period of 7 weeks from completion of 
therapy to bronchodilator therapy. Other anti-cancer 
treatments had also occurred several months prior to 
this trial. 
We conclude that airflow obstruction is a common 
contributory cause of breathlessness in patients with 
bronchial carcinoma. Patients with bronchial carci- 
noma should be specifically asked about breathless- 
ness, and airflow obstruction should be considered as 
a possible diagnosis and treated appropriately. Ben- 
efit can be obtained by treatment in many cases and 
we would suggest that for this group of patients, it is 
appropriate to begin with a &agonist and an anti- 
cholinergic drug via the inhaled route using a large 
volume spacing device. 
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Appendix 
Simple Breathlessness Questionnaire 
Tick one Rating 
Does breathlessness trouble you: 
very much? 0 (3) 
moderately? 0 (2) 
a little? 0 (1) 
not at all? q (0) 
Patients assessment of treatment (for patients in the 
bronchodilator trial) 
This question is about the medication that you 
have used for the last two weeks. 
Tick one Score 
The medication helped my breathing: 
a great deal q (3) 
quite a lot q (2) 
a little q (1) 
not at all 0 (0) 
